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Abstract
Background: The aim of this study was to evaluate the effects of systemic parameters, laboratory findings, oral
parameters, and other ocular surface parameters on ocular surface epithelial damage in patients with primary
Sjögren’s syndrome (pSS).
Methods: A total of 82 dry eye disease (DED) patients with pSS were enrolled in this study. Ocular surface epithelial
damage was measured by ocular staining score (OSS). Systemic parameters, laboratory findings including serologic markers,
oral parameters, and other ocular surface parameters were collected. Other ocular surface parameter assessments such as the
Schirmer’s test, fluorescein tear breakup time, meibomian gland examinations, noninvasive keratographic tear film break-up
time measurements using the Keratograph® 5 M were performed, and the Ocular Surface Disease Index was determined.
Results: In a multivariate analysis, decreased age and increased duration of pSS were significantly related to increased
logarithm-transformed OSS (β = -0.011, P= 0.043 and β= 0.003, P= 0.008). Among the ocular surface parameters, decreased
fluorescein tear breakup time and increased MGD grade were significantly associated with increased logarithm-transformed
OSS (β = -0.183, P< 0.001 and β= 0.192, P= 0.049).
Conclusions: Ocular surface epithelial damage in patients with pSS was associated with young age, long duration of
disease, unstable tear film, and decreased meibomian gland function.
Keywords: Dry eye disease, Primary Sjögren's syndrome, Ocular surface epithelial damage, Ocular staining score, Fluorescein
tear break up time, Meibomian gland dysfunction
Background
Dry eye disease (DED) is a multifactorial ocular surface
disease characterized by a loss of tear film homeostasis
[1, 2]. In the 2017 Tear Film and Ocular Surface society
(TFOS) Dry Eye Workshop (DEWS) II report, DED was
classified into aqueous deficient dry eye (ADDE) and
evaporative dry eye. ADDE is categorized into two
groups, Sjögren’s syndrome (SS)-related dry eye and
non-SS DED [2]. In patients with significant ADDE,
11.6 % had SS: 6.4 % had primary SS (pSS), and 5.2 %
had secondary SS [3].
SS is a systemic autoimmune disease, in which T cells and
autoantibody producing B cells infiltrate exocrine glands,
such as salivary gland and lacrimal gland [4–6]. Th1- and
Th17-associated cytokines, IFN-γ, and IL-17, are all associ-
ated with increased inflammation and glandular dysfunction,
and IL-1 suppress lacrimal acinar secretion [7–9]. This in-
flammation also involves the extragland, which causes symp-
toms of pain, myalgia, and inflammation of the joint,
vascular system, skin, lungs, and kidneys [10]. When SS oc-
curs by itself, it is referred to as pSS, and when accompanied
by another autoimmune disease, it is referred to as secondary
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SS [11]. The diagnosis of pSS is made in combination with at
least 1 symptom of ocular or oral dryness or systemic mani-
festations as well as signs such as ADDE findings; decreased
tear secretion and significant ocular staining score (OSS), the
presence of autoantibodies, evidence of reduced salivary
gland secretion, and positive findings of minor salivary gland
biopsy [12].
In DED, excessive dryness causes tear film hyperosmolar-
ity, which stimulates the production of cytokines from the
ocular surface epithelium [13]. This process activates an in-
flammatory cascade at the ocular surface, which leads to cor-
neal barrier disruption and conjunctival goblet cell
dysfunction [13]. The consequent ocular surface epithelial
damage can be seen in severe DED and as an indicator of
ocular surface epithelial damage, and the OSS has been dem-
onstrated to be an informative marker of disease severity of
DED [14]. Also, the OSS showed positive correlations with
the expression of inflammatory cytokines in SS related DED,
which is an important marker of ocular surface inflammation
[13]. Previous few studies have also reported an association
between the OSS and not only ocular surface inflammation,
but also systemic parameters such as positive serologic find-
ings [15, 16].
The factors that affect ocular surface epithelial damage in
the patients with pSS (Fig. 1a, b) have not been well studied
yet. Furthermore, this type of damage is important in deter-
mining optimal treatment strategies for DED patients with
pSS. Therefore, the purpose of our study was to evaluate the
effects of systemic parameters, laboratory findings, oral pa-
rameters, and other ocular surface parameters on ocular sur-




The study was approved by the Institutional Review
Board (IRB) of Inha University Hospital and it was com-
plied with the tenets of the Declaration of Helsinki. No
written informed consent was required as data was
retrospectively collected from chart review, as approved
by the reference IRB.
This retrospective chart review of patients with SS
among outpatients who visited for management of dry
eye symptoms from March 2015 to July 2019 in the De-
partment of Ophthalmology at Inha University Hospital.
One hundred thirty-five SS patients with recorded ocular
surface parameters (including the OSS) and checkable
medical chart were analyzed, and 73 patients who were
excluded based on the pSS criteria. A total of 82 patients
with DED who were diagnosed with pSS were enrolled
in this study. The American College of Rheumatology/
European League against Rheumatism classification cri-
teria for rheumatoid arthritis (ACR/EULAR) was used to
diagnose pSS [17], which was defined as a score ≥ 4 with
at least 1 symptom of ocular or oral dryness or the pres-
ence of systemic manifestations of SS. We excluded pa-
tients younger than 20 years of age as well as those with
histories of ocular surgery within 6 months, ocular in-
jury, or other ocular diseases.
Outcome measures
The clinical variables, presence of systemic disease, and
previous medical history were investigated. The age was
defined as age at the time of examination of OSS, and
the duration of pSS was defined as the period from the
diagnosis of pSS to the examination of OSS. We assessed
the current medication use at the time of examination of
OSS, at least 3 months of use were included. Oral medi-
cations such as pilocarpine, hydroxychloroquine, metho-
trexate, cyclosporine, and steroid for SS, and topical
medications such as cyclosporine and steroid for DED
were included. The duration of the topical cyclosporine
use was 13.2 months (range, 6–25 months) and topical
steroid use was 11.3 months (range, 3–18 months).
Laboratory parameters included white blood cell,
erythrocyte sedimentation rate, C-reactive protein, com-
plement C3, complement C4, and immunoglobulin G.
Fig. 1 The K5M images of ocular surface staining in two dry eye patients with primary Sjögren’s syndrome (pSS). a Severe ocular surface staining
in a 60-year-old woman with pSS. b Mild ocular surface staining in a 59-year-old woman with pSS
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The positivity of antibodies associated with connective
tissue diseases, such as anti-Sjögren’s-syndrome-related
antigen A(SSA)/Ro, anti- Sjögren’s-syndrome-related
antigen B(SSB)/La, antinuclear antibody (ANA), and
rheumatoid factor (RF), were assessed. The positive
ranges of antibodies are as follows: anti-SSA/Ro anti-
body > 10 U/mL, anti-SSB/La antibody > 10 U/mL,
ANA ≥ 1:80, and RF > 14.0 IU/mL. All laboratory param-
eters were measured at the Inha University Hospital la-
boratory medicine department, and the laboratory
findings closest to the time of examination of OSS at
Inha University hospital ophthalmology outpatient clinic
were used. The average time interval between the la-
boratory findings and examination of OSS was 6.1 ± 6.6
months.
Ocular surface parameters were performed as follows
and data were obtained from the right eye unless the
right eye was excluded from the study, in which case
data were collected from the left eye. (1) OSS according
to the National Eye Institute/Industry Workshop scale
[17–20], which was graded from 0 to 3 for each of the
five areas on cornea and each of the six areas on con-
junctiva. A total score from 0 to 33 based on the pattern
of fluorescein staining observed under the slit lamp. (2)
Subjective symptoms were graded on a numerical scale
from 0 to 4, according to the validated 12-item ocular
surface disease index (OSDI) questionnaire. The total
OSDI, ranging from 0 to 100, was calculated using the
following formula: OSDI = (sum of scores for all ques-
tions answered × 100) / (total number of answered ques-
tions × 4) [18, 20–22]. (3) Schirmer’s test I was
performed without topical anesthesia by placing a Schir-
mer strip in the mid-lateral portion of the lower fornix.
The amount of wetting was recorded after 5 min, and
the patients were asked to keep their eyes lightly closed
during the test. (4) Fluorescein break-up time (FBUT)
was measured through application of a single fluorescein
strip (Haag-Streit, Koeniz, Switzerland) to the inferior
palpebral conjunctiva after instilling a drop of normal
saline. The mean time for three results was recorded. (5)
The lid margins and meibomian glands were checked
for lid margin abnormalities, gland expression, and mei-
bum quality, as previously described [20, 21, 23–27]. Lid
margin abnormalities were scored as 0 (absent) or 1
(present) for the following parameters: vascular engorge-
ment, plugged meibomian gland orifices, anterior or
posterior displacement of the mucocutaneous junction,
and irregularity of the lid margin [21, 23–25, 27]. The
presence of an inflamed lid margin was checked. The de-
gree of meibomian gland expressibility using firm digital
pressure applied on five glands of the central third of the
lower lid was graded as follows: grade 0, all five glands
expressible; grade 1, three to four glands expressible;
grade 2, one to two glands expressible; and grade 3, no
glands expressible [24, 26, 27]. The meibum quality over
eight lower lid glands was graded as follows: grade 0,
clear; grade 1, cloudy; grade 2, cloudy with granular deb-
ris; and grade 3, thick (texture similar to toothpaste).
Each of the eight glands of the lower eyelid was graded
on a scale from 0 to 3. The scores of the eight glands
were summed to obtain a total score (range, 0–24) [21,
24, 27]. The meibomian gland dysfunction (MGD) stage
was determined based on the three lid parameters: MGD
stage 1, minimally altered expressibility (grade 1) and se-
cretion quality (2 ≤ grade < 4); MGD stage 2, scattered
lid margin features, mildly altered expressibility (grade
1) and secretion quality (4 ≤ grade < 8); MGD stage 3, lid
margin features of plugging, vascularity, moderately al-
tered expressibility (grade 2) and secretion quality (8 ≤
grade < 13); MGD stage 4, lid margin features of drop-
out, displacement, severely altered expressibility (grade
3), and secretion quality (grade ≥ 13) [23, 27]. (6) Tear
film assessment with the “TF-Scan, Non-Invasive Kera-
tograph® Break-Up Time (NIKBUT) mode” was con-
ducted when the subjects were instructed to blink three
or four times and then keep their eyes open for as long
as possible. Irregularities on the image indicated instabil-
ity or breakup of the tear film and, at the same time, a
video was recorded. The device provided a representa-
tion of tear film break up over time, including a tear film
map showing the location and size of the tear film-break
regions, as well as the first break-up time (NIKBUT-
first) and the average break-up time (NIKBUT-average;
the mean of all tear film break-ups occurring over the
entire cornea), as previously described [20, 28, 29].
Oral parameters included subjective oral symptom score,
non-stimulated whole salivary flow (NSWSF), and positivity
of a minor salivary gland biopsy. The subjective oral symp-
tom score was based on the 2002 American-European Con-
sensus Group (AECG) criteria, and three questions were
summed to obtain a total score (range, 0–3): (1) symptoms
of dry mouth for at least 3 months, (2) recurrent or persist-
ently swollen salivary glands, and (3) need for liquids to swal-
low dry foods [17]. NSWSF reflects the basal flow from all
glands. Patients must swallow any residual saliva before start-
ing the procedure and allow all saliva to accumulate in the
mouth and spit it every minute. Saliva was collected for 15
minutes and the measured volume was expressed in mL/
min. For the SS criteria, a value ≤ 0.1 mL/min was considered
abnormal [17, 30]. Minor salivary gland biopsy positivity was
determined based on the AECG criteria, which was defined
as a focus score of 1 or more. Focus was defined as a dense
aggregate of 50 or more lymphocytes in a 4-mm2 area of the
glandular tissue [17].
Statistical analyses
Statistical analyses were performed using SPSS for Win-
dows (version 20.0; SPSS Inc., Chicago, IL, USA). The
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OSS was logarithm-transformed to be approximately
normally distributed. Univariate and multivariate linear
regression analyses were computed to evaluate the im-
pact of systemic and laboratory parameters, oral parame-
ters, and other ocular surface parameters on the
logarithm-transformed OSS. For the multivariate linear
regression analysis, age, sex, and other variables with P
value less than 0.1 in the univariate model were in-
cluded. In all tests, a P value less than 0.05 was consid-
ered significant.
Results
A total of 82 DED patients with pSS were included in
this study. Table 1 shows the clinical variables, presence
of systemic disease, and previous medical history of 82
patients. The mean age was 53.8 years old (range, 24–
80 years), and 78 patients (95.1 %) were women. The
mean duration of pSS was 39.4 months (range, 1–
185 months). The laboratory findings and oral parame-
ters of all 82 patients are summarized in Table 2: 77.2 %
of the patients were positive for anti-SSA/Ro, 38.6 %
were positive for anti-SSB/La, and the proportion of
both positive were 41.5 %. 63.4 % were positive for ANA,
and 43.8 % were positive for RF. The ocular surface
parameters and keratographic parameters of the 82 pa-
tients are summarized in Table 3: the mean OSS was
7.65 ± 5.06 (range, 0–26).
The results of univariate linear regression analysis are
summarized in Tables 1, 2 and 3. The duration of pSS,
topical cyclosporine history, anti-SSB/La antibody, RF,
MGD stage, and subjective oral score were positively as-
sociated with logarithm-transformed OSS. FBUT, Schir-
mer’s test-I value, NSWSF were negatively associated
with logarithm-transformed OSS (all P < 0.050).
In the multivariate linear regression analysis, age, sex,
and statistically significant or borderline significant (P
value less than 0.1) variables were included. After adjust-
ing for other factors, decreased age and increased dur-
ation of pSS were significantly related to increased
logarithm-transformed OSS. (β = -0.011, P = 0.043 for
age; β = 0.003, P = 0.008 for duration of pSS). After
adjusting for other factors, positive serology or oral pa-
rameters was not related to OSS in our study. Among
the ocular surface parameters, decreased FBUT and in-
creased MGD grade were significantly associated with
increased logarithm-transformed OSS (β = -0.183, P <
0.001 for FBUT; β = 0.192, P = 0.049 for MGD grade)
(Table 4).
Discussion
The aim of this study was to identify the factors associ-
ated with ocular surface epithelial damage in patients
with pSS. We evaluated the effects of systemic parame-
ters, laboratory findings, oral parameters, and other ocu-
lar surface parameters on ocular surface epithelial
damage in patients with pSS. Ocular surface epithelial
damage was measured by OSS, which is sum of corneal
and conjunctival staining score. The OSS is included in
the criteria for pSS with Schirmer’s test, and it is an in-
formative marker for the severity of DED [12, 14]. Be-
cause ocular surface epithelial damage could affect visual
disturbance and indicates the presence of ocular surface
inflammation, the OSS parameter is important for deter-
mining treatment for DED patients with pSS [13, 16,
31].
Previous studies have reported that an association be-
tween dry eye and systemic parameters, or extraocular
variables [11, 16, 32–35]. They used the symptoms of
ocular dryness, tear osmolarity, or severe DED severity,
as indicators of DED. Similar to our study, few studies
used the OSS as the main outcome variable, but only re-
ported correlations with laboratory findings, such as
positive serologic findings [15, 16]. Therefore, we fo-
cused on the OSS as the main outcome and analyzed its
independent association with systemic parameters, la-
boratory findings, oral parameters, and other ocular sur-
face parameters after adjusting other variables.
Table 1 The systemic parameters and univariate analysis of
these parameters on logarithm transformed ocular staining
score




Age (y) 53.8 ± 11.2 (24-80) 0.009 (0.006) 0.136
Sex, n (%)
Male 4 (4.9%) 1 (Ref)
Female 78 (95.1%) 0.005 (0.309) 0.988
Duration of disease (m) 39.4 ± 45.4 (1-185) 0.003 (0.001) 0.029
Systemic disease, n (%)
No history 61 (74.4%) 1 (Ref)
Hypertension 16 (19.5%) 0.144 (0.167) 0.389
Diabetes mellitus 3 (3.7%) 0.250 (0.353) 0.482
Ocular surgery history, n (%)
No history 69 (84.1%) 1 (Ref)
Refractive surgery 6 (7.3%) -0.356 (0.252) 0.162
Pharmacological history, n (%)
Oral Pilocarpine 16 (19.5%) -0.024 (0.134) 0.857
Oral Hydroxychloroquine 3 (3.7%) -0.134 (0.147) 0.365
Oral Methotrexate 15 (18.3%) -0.029 (0.172) 0.864
Oral Cyclosporine 3 (3.7%) 0.413 (0.351) 0.243
Oral Steroid 14 (17.1%) 0.204 (0.175) 0.246
Topical Cyclosporine 3 (3.7%) 0.551 (0.185) 0.004
Topical Steroid 11 (13.4%) 0.218 (0.175) 0.217
DED dry eye disease, pSS primary Sjögren’s syndrome, SE standard error
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Among the systemic parameters, age and duration of
pSS were significant factors that influenced OSS in the
multivariate analysis of our study. A decrease in age was
significantly related to an increase in OSS after adjusting
for other factors. Although the previous studies of ocular
parameters in patients with pSS have reported a correl-
ation with age, they mostly have found a correlation with
onset age of pSS or with ocular symptoms other than
OSS [32–36]. In their study, the age was negatively re-
lated to ocular dryness, indicating older patients with se-
vere disease tended to be less sensitive [32].
In another study, young-onset SS (age at diagnosis <
35 years) correlation with xerostomia (P = 0.008), abnor-
mality of Schirmer’s test and/or Rose Bengal staining
(P = 0.03), positivity of anti-Ro/SS-A antibodies (P <
0.001), low complement C3 (P = 0.018) and low comple-
ment C4 levels (P = 0.017), compare to age at diagnosis >
35 years [33].
An increase of the duration of pSS was significantly re-
lated to an increase of OSS in the current study. A previ-
ous study with a large cohort study of patients with pSS
in Spain also reported a correlation between duration of
Table 2 Laboratory findings, oral parameters, and univariate analysis of these parameters on logarithm-transformed ocular staining
score
Variables Mean ± SD Univariate analysis
Beta (SE) P-value
Laboratory findings
White blood cell (/μL) 5122.56 ± 1496.99 0.000 (0.000) 0.350
Erythrocyte sedimentation rate (mm/h) 17.09 ± 13.46 0.006 (0.005) 0.262
C-reactive protein (mg/dL) 0.14 ± 0.33 0.138 (0.203) 0.498
Complement C3 (mg/dL) 105.68 ± 19.71 (68a) 0.003 (0.004) 0.471
Complement C4 (mg/dL) 21.79 ± 8.32 (68a) 0.005 (0.009) 0.563
Immunoglobulin G (mg/dL) 1412.61 ± 407.95 (38a) 0.000 (0.000) 0.124
Positive serology % (n)
Anti-SSA/Ro antibody 77.2 (61/79a) 0.274 (0.157) 0.086
Anti-SSB/La antibody 38.6 (27/70a) 0.504 (0.140) 0.001
Antinuclear antibody, (≥1: 80) 63.4 (52/82a) 0.235 (0.135) 0.087
Rheumatoid factor 43.8 (35/80a) 0.315 (0.132) 0.020
Oral parameters
Subjective oral score (0-3) 1.58 ± 0.71 0.258 (0.093) 0.007
Non-stimulated whole salivary flow (mL/min) 0.09 ± 0.09 (79a) -0.122 (0.047) 0.011
Positive results of salivary gland biopsy, % (n) 73.7 (14/19a) 0.119 (0.293) 0.688
aRepresented the actual number of patients who underwent the test
SD standard deviation, SSA Sjögren's-syndrome-related antigen A, SSB Sjögren's-syndrome-related antigen B; SE standard error
Table 3 Ocular surface parameters and univariate analysis of these parameters on logarithm-transformed ocular staining score
Variables Mean ± SD Univariate analysis
Beta (SE) P-value
Ocular surface parameters
Ocular staining score (0-33), NEI scale 7.65 ± 5.06
Subjective score (OSDI) 41.63 ± 22.88 0.004 (0.003) 0.179
Schirmer’s test I value (mm) 7.01 ± 6.83 -0.038 (0.008) <0.001
FBUT (seconds) 2.30 ± 1.67 -0.230 (0.026) <0.001
MGD grade (0–4) 1.95 ± 0.74 0.432 (0.076) <0.001
Parameters using K5M
NIKBUT-first (seconds) 4.31 ± 1.73 -0.069 (0.035) 0.054
NIKBUT-average (seconds) 8.20 ± 3.12 -0.026 (0.020) 0.193
K5M Keratograph®5M, FBUT fluorescein break-up time, MGD meibomian gland dysfunction, NEI National Eye Institute, NIKBUT non-invasive Keratograph® break-up
time, OSDI ocular surface disease index, SE standard error
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pSS and ocular involvement. Patients who had longer
duration of pSS (more than 10 years) showed a higher
prevalence of xerophthalmia, abnormality of Schirmer’s
test and/or Rose Bengal staining and other systemic in-
volvements (parotid enlargement, lung involvement, vas-
culitis, or peripheral neuropathy), laboratory findings
(positivity of anti-SSA/Ro antibody, anti-SSB/La anti-
body, and low complement C4 level) in a univariate ana-
lysis. But in a multivariate analysis, there were no
significant correlations with xerophthalmia and abnor-
mality of Schirmer’s test and/or Rose Bengal staining
that influence duration of pSS after adjusting for other
factors [33]. According to this our study, patients with
young age and long duration of pSS have higher risk of
ocular surface damage; therefore, more careful monitor
of DED is needed in those patients with pSS.
In our study, among the medical history, topical cyclo-
sporine was associated with increased OSS in univariate
analysis. This may have been due to the fact that topical
cyclosporine was prescribed as treatment in order to im-
prove the OSS in patients with severe ocular surface epi-
thelial damage. However, after adjusting for other
factors, no significant association was found in the
multivariate analysis.
Of the laboratory findings in our study, positivity of
anti-SSB/La antibody and RF were significant variables,
and positivity of anti-SSA/Ro antibody and ANA were
borderline significant variables in the univariate analysis.
This result was similar with previous studies, that re-
ported a correlation between the ocular surface parame-
ters and serologic markers in patients with pSS [3, 15,
16]. Serum RF, and ANA levels correlated with conjunc-
tival staining score and total OSS in patients with pSS
[15]. Furthermore, serum anti-Ro/SSA and anti-La/SSB
antibodies were significantly related with clinical severity
of keratoconjunctivitis sicca based on the Oxford OSS
scheme in patients with pSS [16]. These studies sug-
gested that these parameters could be considered as
prognostic factors for predicting the severity and prog-
nosis of DED in patients with pSS [15, 16]. However, in
our multivariate analysis, there were no significant la-
boratory findings that influenced OSS after adjusting for
other factors. This was the first multivariate analysis
study of association between serologic markers and OSS,
and the results might differ compare to previous studies
that performed a univariate analysis.
Among the oral parameters, positive subjective oral
score and NSWSF were significantly related with OSS in
Table 4 Univariate and multivariate analysis of variables on logarithm-transformed ocular staining score
Variables Univariate analysis Multivariate analysis
Beta (SE) P-value Beta (SE) P-value
Age (y) 0.009 (0.006) 0.136 -0.011 (0.005) 0.043
Sex, n (%)
Male 1 (Ref) 1 (Ref)
Female 0.005 (0.309) 0.988 -0.097 (0.250) 0.699
Duration of disease (m) 0.003 (0.001) 0.029 0.003 (0.001) 0.008
Pharmacological history, n (%)
Topical Cyclosporine 0.551 (0.185) 0.004 -0.008 (0.161) 0.962
Positive serology % (n)
Anti-SSA/Ro antibody 0.274 (0.157) 0.086 -0.082 (0.144) 0.572
Anti-SSB/La antibody 0.504 (0.140) 0.001 0.103 (0.142) 0.476
Antinuclear antibody, (≥1: 80) 0.235 (0.135) 0.087 0.191 (0.122) 0.123
Rheumatoid factor 0.315 (0.132) 0.020 0.096 (0.114) 0.404
Ocular surface parameters
Schirmer’s test I value (mm) -0.038 (0.008) <0.001 -0.012 (0.007) 0.105
FBUT (seconds) -0.230 (0.026) <0.001 -0.183 (0.033) <0.001
MGD grade (0–4) 0.432 (0.076) <0.001 0.192 (0.095) 0.049
Parameters using K5M
NIKBUT-first (seconds) -0.069 (0.035) 0.054 0.053 (0.030) 0.084
Oral parameters
Subjective oral score (0–3) 0.258 (0.093) 0.007 0.074 (0.067) 0.279
NSWSF (mL/min) -0.122 (0.047) 0.011 -0.025 (0.045) 0.578
K5M Keratograph®5M, FBUT fluorescein break-up time, MGD meibomian gland dysfunction, NEI National Eye Institute, NIKBUT non-invasive Keratograph® break-up
time, NSWSF non-stimulated whole salivary flow, SE standard error, SSA Sjögren's-syndrome-related antigen A, SSB Sjögren's-syndrome-related antigen B
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the univariate analysis; however, after adjusting for other
factors, no significant correlation was found. In a recent
rheumatologic study, only the presence of inflammatory
joint involvement among other systemic manifestations
was associated with severe/very severe DED in patients
with pSS (odds ratio, 2.079) [35]. Similarly, a multivari-
ate analysis was performed in this study, thereby show-
ing that there were no associations between other
laboratory findings or oral parameters and DED severity.
Among the ocular surface parameters, FBUT and MGD
were significant factors that influenced OSS in the multi-
variate analysis of our study. An increase in FBUT was sig-
nificantly related to an increase in OSS after adjusting for
other factors. The results of the Schirmer’s test were sig-
nificantly related with OSS in the univariate analysis, but
no significant correlation was found after adjusting for
other factors. According to previous study of patients with
DED and ocular surface disease, FBUT is minimally inva-
sive test and is a more reliable than the Schirmer’s test.
Furthermore, FBUT is strongly correlated with other ocu-
lar tests such as OSS [37]. From these results, FBUT
reflected the ocular surface epithelial damage better than
the Schirmer’s test even in patients with pSS.
An increase in MGD grade was significantly related to
an increase in OSS after adjusting for other factors. A
previous study on MGD in patients with pSS reported
that changes in the meibomian gland induced an in-
crease of tear evaporation and subsequent worsening of
the ocular surface desiccation [38]. Furthermore, in an-
other study, morphological and functional features of
the meibomian gland correlated with other ocular sur-
face parameters and disease severity in ADDE, such as
pSS and graft-versus-host disease [39]. According to this
result, more attention is needed in pSS patients with low
FBUT and severe MGD, which could cause more ocular
surface epithelial damage.
There were several limitations in this study. First, the
retrospective of the study might lead to unexpected vari-
ous bias. Second, only a small number of patients were
enrolled. Third, some of the parameters were not
assessed in some of the patients. Fourth, some systemic
manifestations, such as inflammatory joint involvement,
were not evaluated in this study. Because of these limita-
tions, it is necessary to conduct a prospective study in
the future. However, our study is meaningful because it
is the first multivariate regression analysis of factors as-
sociated with ocular surface epithelial damage in patients
with pSS.
Conclusions
In conclusion, ocular surface epithelial damage in pa-
tients with pSS was associated with young age, long dur-
ation of disease, unstable tear film, and decreased
meibomian gland function.
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